Anti-IL5 therapy for severe asthma: Towards a MAB war?

被引：0
作者：
Le Borgne-Krams, A. [1 ]
Guilleminault, L. [2 ,3 ,4 ]
Mailhol, C. [1 ]
Didier, A. [1 ]
机构：
[1] CHU Toulouse, Hop Larrey, Pole Voies Resp, 24 Chemin Pouvourville, F-31059 Toulouse 9, France
[2] CHU Reunion, GHSR, Pneumol, BP 350, F-97448 St Pierre, Reunion, France
[3] INSERM, Plateforme CYROI, UMR 1188, Diabet Atherothrombose Therapies Reunion Ocean In, F-97490 St Clotilde, Reunion, France
[4] Univ La Reunion, UMR 1188, F-97490 St Clotilde, Reunion, France
来源：
REVUE FRANCAISE D ALLERGOLOGIE | 2016年 / 56卷 / 7-8期
关键词：
Asthma; Eosinophil; IL-5; Biotherapies; Benralizumab; Mepolizumab; Reslizumab; SEVERE EOSINOPHILIC ASTHMA; ALPHA MONOCLONAL-ANTIBODY; DOUBLE-BLIND; BENRALIZUMAB; MEPOLIZUMAB; PLACEBO; ANTI-INTERLEUKIN-5; INTERLEUKIN-5; RESLIZUMAB; ADULTS;
D O I：
10.1016/j.reval.2016.08.003
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
The presence of eosinophilic inflammation is the most frequent clinical phenotype encountered in patients with severe asthma. Interleukin-5 (IL-5) is a pro-inflammatory cytoldne that plays a pivotal pathogenic role in eosinophilic asthma; it is involved in eosinophil differentiation, activation and tissue migration, and it is equally involved in eosinophil survival and the prevention of apoptosis. Several monoclonal antibodies (MABs) targeting IL-5 or its cellular receptor are currently being developed for the treatment of severe asthma. We discuss their mode of action and the results observed in recently published clinical trials. It seems that, generally, anti-IL-5 therapies have as their target a reduction of the frequency of asthma exacerbations and improvement of clinical and lung function parameters in selected patients with severe asthma and an eosinophilic phenotype. This new therapeutic class of drugs should certainly lead to improvement in the management of patients with persistent severe eosinophilic asthma who have not responded to currently available anti-asthmatic treatment. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：549 / 555
页数：7
相关论文
共 42 条
[1]   An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis [J].
Ahmadi, Zahra ;
Hassanshahi, Gholamhossein ;
Khorramdelazad, Hossein ;
Zainodini, Nahid ;
Koochakzadeh, Leila .
INFLAMMATION, 2016, 39 (03) :1253-1267
[2]   Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].
Bel, Elisabeth H. ;
Wenzel, Sally E. ;
Thompson, Philip J. ;
Prazma, Charlene M. ;
Keene, Oliver N. ;
Yancey, Steven W. ;
Ortega, Hector G. ;
Pavord, Ian D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197
[3]   Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study [J].
Bjermer, Leif ;
Lemiere, Catherine ;
Maspero, Jorge ;
Weiss, Sivan ;
Zangrilli, James ;
Germinaro, Matthew .
CHEST, 2016, 150 (04) :789-798
[4]   Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study [J].
Brightling, Christopher E. ;
Bleecker, Eugene R. ;
Panettieri, Reynold A., Jr. ;
Bafadhel, Mona ;
She, Dewei ;
Ward, Christine K. ;
Xu, Xiao ;
Birrell, Claire ;
van der Merwe, Rene .
LANCET RESPIRATORY MEDICINE, 2014, 2 (11) :891-901
[5]   Eosinophilic airway inflammation in nonallergic asthma [J].
Brusselle, Guy G. ;
Maes, Tania ;
Bracke, Ken R. .
NATURE MEDICINE, 2013, 19 (08) :977-979
[6]   Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions [J].
Büttner, C ;
Lun, A ;
Splettstoesser, T ;
Kunkel, G ;
Renz, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) :799-803
[7]  
Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]
[8]   Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study [J].
Castro, Mario ;
Wenzel, Sally E. ;
Bleecker, Eugene R. ;
Pizzichini, Emilio ;
Kuna, Piotr ;
Busse, William W. ;
Gossage, David L. ;
Ward, Christine K. ;
Wu, Yanping ;
Wang, Bing ;
Khatry, Deepak B. ;
van der Merwe, Rene ;
Kolbeck, Roland ;
Molfino, Nestor A. ;
Raible, Donald G. .
LANCET RESPIRATORY MEDICINE, 2014, 2 (11) :879-890
[9]   Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study [J].
Castro, Mario ;
Mathur, Sameer ;
Hargreave, Frederick ;
Boulet, Louis-Philippe ;
Xie, Fang ;
Young, James ;
Wilkins, H. Jeffrey ;
Henkel, Timothy ;
Nair, Parameswaran .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (10) :1125-1132
[10]  
Chung KF, 2014, EUR RESPIR J, V44, P1378, DOI 10.1183/09031936.00120714
12345